Besides the above, variations of the glucokinase regulator (GCKR) gene locus have been reported to be associated with NAFLD, and various studies have demonstrated the roles of other genetic variations in the regulation of lipid metabolism (LYPLAL1, APOB, MTP, LPIN1, UCP2), innate immunity (IL28B, MERTK), insulin signaling (ENPP1, IRS1), oxidative stress (SOD2), and fibrogenesis (KLF6) in relation to the progression of NAFLD [24] (Figure 1). This evidence concerns the gene LYPLAL1 and metabolic dysfunction-associated steatotic liver disease.